JP6837434B2 - 抗ｂ型インフルエンザ抗体の中和及びその使用 - Google Patents

抗ｂ型インフルエンザ抗体の中和及びその使用 Download PDF

Info

Publication number
JP6837434B2
JP6837434B2 JP2017523183A JP2017523183A JP6837434B2 JP 6837434 B2 JP6837434 B2 JP 6837434B2 JP 2017523183 A JP2017523183 A JP 2017523183A JP 2017523183 A JP2017523183 A JP 2017523183A JP 6837434 B2 JP6837434 B2 JP 6837434B2
Authority
JP
Japan
Prior art keywords
antibody
seq
influenza
antigen
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017523183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523805A (ja
JP2017523805A5 (enExample
Inventor
コルティ，ダヴィデ
ランザヴェッキア，アントニオ
カールワード−リレイ，ニコル
ジュー，チン
ベンジャミン，エボニー
ウェヒター，レスリー
ユアン，アンディ
マコーリフ，ジョセフィン，メアリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Publication of JP2017523805A publication Critical patent/JP2017523805A/ja
Publication of JP2017523805A5 publication Critical patent/JP2017523805A5/ja
Application granted granted Critical
Publication of JP6837434B2 publication Critical patent/JP6837434B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017523183A 2014-07-15 2015-07-14 抗ｂ型インフルエンザ抗体の中和及びその使用 Active JP6837434B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462024804P 2014-07-15 2014-07-15
US62/024,804 2014-07-15
PCT/US2015/040385 WO2016011035A2 (en) 2014-07-15 2015-07-14 Neutralizing anti-influenza b antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021018692A Division JP7209754B2 (ja) 2014-07-15 2021-02-09 抗ｂ型インフルエンザ抗体の中和及びその使用

Publications (3)

Publication Number Publication Date
JP2017523805A JP2017523805A (ja) 2017-08-24
JP2017523805A5 JP2017523805A5 (enExample) 2018-08-23
JP6837434B2 true JP6837434B2 (ja) 2021-03-03

Family

ID=55079157

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017523183A Active JP6837434B2 (ja) 2014-07-15 2015-07-14 抗ｂ型インフルエンザ抗体の中和及びその使用
JP2021018692A Active JP7209754B2 (ja) 2014-07-15 2021-02-09 抗ｂ型インフルエンザ抗体の中和及びその使用
JP2023001445A Active JP7453430B2 (ja) 2014-07-15 2023-01-10 抗ｂ型インフルエンザ抗体の中和及びその使用
JP2024034654A Pending JP2024069341A (ja) 2014-07-15 2024-03-07 抗ｂ型インフルエンザ抗体の中和及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021018692A Active JP7209754B2 (ja) 2014-07-15 2021-02-09 抗ｂ型インフルエンザ抗体の中和及びその使用
JP2023001445A Active JP7453430B2 (ja) 2014-07-15 2023-01-10 抗ｂ型インフルエンザ抗体の中和及びその使用
JP2024034654A Pending JP2024069341A (ja) 2014-07-15 2024-03-07 抗ｂ型インフルエンザ抗体の中和及びその使用

Country Status (10)

Country Link
US (6) US10294292B2 (enExample)
EP (1) EP3169407A4 (enExample)
JP (4) JP6837434B2 (enExample)
CN (4) CN106573154B (enExample)
AU (3) AU2015289805B2 (enExample)
BR (1) BR112017000640A2 (enExample)
CA (1) CA2954780A1 (enExample)
MX (3) MX392761B (enExample)
RU (2) RU2711932C2 (enExample)
WO (1) WO2016011035A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2837392T3 (es) 2013-10-02 2021-06-30 Medimmune Llc Anticuerpos anti-influenza A neutralizantes y usos de los mismos
CN106573154B (zh) 2014-07-15 2021-06-15 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
BR112017025496A2 (pt) * 2015-06-01 2018-08-07 Medimmune, Llc Moléculas de ligação neutralizantes anti- influenza e usos das mesmas
US20190015509A1 (en) 2016-01-13 2019-01-17 Medimmune, Llc Method of treating influenza a
EP4051707A1 (en) * 2019-10-28 2022-09-07 Regeneron Pharmaceuticals, Inc. Anti-hemagglutinin antibodies and methods of use thereof
CN112048006B (zh) * 2020-09-08 2021-04-27 扬州大学 一种替代中和效力测定的elisa方法及其应用
WO2023102398A2 (en) * 2021-11-30 2023-06-08 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof
CN118420751B (zh) * 2022-07-09 2025-04-08 东莞市朋志生物科技有限公司 抗乙型流感病毒抗体、检测乙型流感病毒的试剂和试剂盒

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6071251A (en) 1996-12-06 2000-06-06 Abbott Laboratories Method and apparatus for obtaining blood for diagnostic tests
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
JP4528989B2 (ja) * 1999-03-31 2010-08-25 学校法人慶應義塾 インフルエンザウイルス・ヘマグルチニン結合性ペプチド
JP4656478B2 (ja) 2000-02-22 2011-03-23 株式会社医学生物学研究所 抗体ライブラリー
ATE309385T1 (de) 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
EP1551875A4 (en) 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
US7175999B2 (en) 2002-07-11 2007-02-13 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
CN1934133B (zh) 2003-07-23 2011-12-14 富士瑞必欧株式会社 抗a型流感病毒单克隆抗体及使用该抗体的免疫测定器具
EP1666059A4 (en) 2003-08-11 2008-08-27 Univ Osaka Res Found NEW VACCINE WITH AN ADJUVANS FOR TRIGGERING ABSORBENT IMMUNITY
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
US8716557B2 (en) 2006-01-17 2014-05-06 Synthon Biopharmaceuticals B.V. Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in plants
CA2647380A1 (en) 2006-03-21 2007-09-27 David T. Weaver Methods for humanizing antibodies and humanized antibodies made thereby
US7615220B2 (en) 2006-04-07 2009-11-10 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-18 receptor
US20080014205A1 (en) 2006-05-15 2008-01-17 Lawrence Horowitz Neutralizing Antibodies to Influenza Viruses
US8192927B2 (en) 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
MX2009003393A (es) 2006-10-02 2009-05-11 Regeneron Pharma Anticuerpos humanos de alta afinidad para el receptor de il-4 humano.
WO2008066691A2 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
WO2008110937A2 (en) 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
AU2009275226B2 (en) 2008-07-25 2015-05-14 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
EP4071169A2 (en) 2008-08-25 2022-10-12 Dana Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
EP2356146A1 (en) 2008-11-07 2011-08-17 Fabrus Llc Anti-dll4 antibodies and uses thereof
US9534042B2 (en) * 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
EP2652496B1 (en) 2010-12-13 2018-01-17 The University of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
CN103906763B (zh) * 2011-07-14 2016-10-12 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子
SI2734545T1 (sl) 2011-07-18 2019-06-28 Institute For Research In Biomedicine Protitelesa, ki nevtralizirajo virus influence A in njihova uporaba
US10131695B2 (en) 2011-09-20 2018-11-20 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
EP2776061B1 (en) * 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
WO2013086052A2 (en) * 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
WO2013132007A1 (en) * 2012-03-08 2013-09-12 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
EA201892509A1 (ru) 2012-11-13 2019-04-30 Дженентек, Инк. Антитела к гемагглютинину и способы применения
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
RU2536956C1 (ru) 2013-08-05 2014-12-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
ES2837392T3 (es) 2013-10-02 2021-06-30 Medimmune Llc Anticuerpos anti-influenza A neutralizantes y usos de los mismos
CN106573154B (zh) * 2014-07-15 2021-06-15 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
BR112017025496A2 (pt) 2015-06-01 2018-08-07 Medimmune, Llc Moléculas de ligação neutralizantes anti- influenza e usos das mesmas
US20190015509A1 (en) 2016-01-13 2019-01-17 Medimmune, Llc Method of treating influenza a
JP7104629B2 (ja) 2016-02-24 2022-07-21 ビステラ， インコーポレイテッド インフルエンザウイルスに対する抗体分子の製剤

Also Published As

Publication number Publication date
BR112017000640A2 (pt) 2017-11-14
RU2020100073A (ru) 2020-03-03
RU2739952C2 (ru) 2020-12-30
RU2711932C2 (ru) 2020-01-23
CN113563462B (zh) 2024-08-13
CN113173990B (zh) 2024-10-29
AU2015289805B2 (en) 2020-06-25
US20240076357A1 (en) 2024-03-07
US11787853B2 (en) 2023-10-17
JP2021074013A (ja) 2021-05-20
JP2017523805A (ja) 2017-08-24
CN113173990A (zh) 2021-07-27
CN106573154A (zh) 2017-04-19
US10519221B2 (en) 2019-12-31
US20220025020A1 (en) 2022-01-27
CN119161468A (zh) 2024-12-20
AU2024202231A1 (en) 2024-05-02
CA2954780A1 (en) 2016-01-21
JP7209754B2 (ja) 2023-01-20
RU2017104638A3 (enExample) 2019-07-17
WO2016011035A8 (en) 2016-12-08
MX2022006558A (es) 2022-07-11
JP2024069341A (ja) 2024-05-21
JP2023052268A (ja) 2023-04-11
AU2020233635A1 (en) 2020-10-08
EP3169407A2 (en) 2017-05-24
RU2020100073A3 (enExample) 2020-06-10
CN113563462A (zh) 2021-10-29
MX392761B (es) 2025-03-21
AU2020233635B2 (en) 2024-01-18
US10294292B2 (en) 2019-05-21
US20190233504A1 (en) 2019-08-01
US20250263470A1 (en) 2025-08-21
WO2016011035A3 (en) 2016-03-10
CN106573154B (zh) 2021-06-15
US20200190169A1 (en) 2020-06-18
RU2017104638A (ru) 2018-08-15
WO2016011035A2 (en) 2016-01-21
AU2015289805A1 (en) 2017-03-02
EP3169407A4 (en) 2018-04-25
JP7453430B2 (ja) 2024-03-19
MX2022006561A (es) 2022-07-11
US20170218054A1 (en) 2017-08-03
US11174304B2 (en) 2021-11-16
US12325740B2 (en) 2025-06-10
MX2017000595A (es) 2017-10-12

Similar Documents

Publication Publication Date Title
JP7060653B2 (ja) 抗ａ型インフルエンザ抗体の中和及びその使用
US12325740B2 (en) Neutralizing anti-influenza B antibodies and uses thereof
RU2784915C2 (ru) Нейтрализующие антитела к вирусу гриппа b и пути их применения
HK40061870A (en) Neutralizing anti-influenza b antibodies and uses thereof
HK40057425A (en) Neutralizing anti-influenza b antibodies and uses thereof
HK40057425B (zh) 中和抗乙型流感抗体及其用途
HK40061870B (zh) 中和抗乙型流感抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170720

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210209

R150 Certificate of patent or registration of utility model

Ref document number: 6837434

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250